ArticleFrontiers in oncology2025
Case Report: Postoperative cervical lymph node metastasis of the neuroendocrine carcinoma component of rectal mixed adenoneuroendocrine carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mixed adenoneuroendocrine carcinoma of the gallbladder: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Clinical case reports of rectal mixed neuroendocrine-non-neuroendocrine tumors are rare. This report highlights a case in which only the neuroendocrine carcinoma component metastasized to the lymph nodes seven years postoperatively, and its successful treatment. Case description: A 73-year-old male was admitted to our hospital in November 2015 with rectal bleeding lasting more than four months. A mass was detected and radical surgery and preventive ileostomy was performed, followed by six cycles of chemotherapy. Postoperative pathology revealed two distinct histological patterns, representing the adenocarcinoma and neuroendocrine components; 6 of 12 mesenteric lymph nodes tested positive, whereas 2 pelvic lymph nodes were negative. The patient presented again on April 30, 2022, with multiple palpable masses of varying sizes in the right side of the neck. A biopsy revealed a metastatic poorly differentiated carcinoma consistent with neuroendocrine carcinoma in the right cervical lymph nodes, which was considered to originate from the rectum. The patient again underwent surgery and six rounds of chemotherapy, which resulted in a significant reduction in the size of the cervical lymph nodes. Discussion: Due to the highly malignant nature of mixed adenoneuroendocrine carcinoma, early diagnosis and treatment are crucial for improving patient survival and therapeutic outcomes. A comprehensive, individualized treatment plan involving surgery, chemotherapy, targeted therapy, and immunotherapy can provide better patient outcomes. Given the metastatic potential of mixed adenoneuroendocrine carcinoma, long-term postoperative follow-up is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.